<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962558</url>
  </required_header>
  <id_info>
    <org_study_id>MT-T-02</org_study_id>
    <secondary_id>2U44DC010084-04</secondary_id>
    <nct_id>NCT01962558</nct_id>
  </id_info>
  <brief_title>Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus</brief_title>
  <official_title>A Blinded Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus vs. VNS With Unpaired Tones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroTransponder Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>MicroTransponder Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and efficacy of VNS paired with tones for tinnitus using a randomized,
      controlled, parallel study design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have moderate to severe tinnitus, at least one year post diagnosis, may enroll.
       All patients will be implanted and randomized to one of two groups:

        -  a group receiving VNS paired with tones and;

        -  a group that receives VNS and tones, but with different settings.

      After device use training, therapy is delivered at home by the patient for 6 weeks.
      Patients have eight baseline audiometric assessments along with two questionnaire
      assessments, an assessment after recovery before treatment starts, and tinnitus assessments
      every two weeks during therapy through the 6 week randomized portion of the study.  After
      the randomized portion, all patients receive VNS paired with tones.  Patients will continue
      to return for quarterly visits and tinnitus assessments through the first year after
      implant, regardless of their therapy status.  Interested patients can continue to receive
      longer-term treatment after the first year.  A goal of up to 30 patients enrolled and
      implanted across four sites is planned for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the number of serious adverse events during the study, and compare between groups to indicate if there are more in the treatment group than the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the number of adverse events during the study, and compare between groups to indicate if there are more in the treatment group than the control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum masking level (MML) in units of dB (decibels)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Asses the change in minimum masking level (MML) for both groups and compare between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinnitus Handicap Inventory (THI)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the change in THI score for both groups and compare between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinnitus Handicap Questionnaire (THQ)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the change in THQ score for both groups and compare between the groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the change in BDI score for both groups and compare between the groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess the change in STAI score for both groups and compare between the groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tinnitus Functional Index (TFI)</measure>
    <time_frame>6-weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the change in TFI score for both groups and compare between the groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>VNS Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VNS Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNS Treatment</intervention_name>
    <description>VNS is given in brief bursts over a 2.5 hour period.  The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.</description>
    <arm_group_label>VNS Treatment</arm_group_label>
    <other_name>VNS paired with tones</other_name>
    <other_name>Serenity System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNS Control</intervention_name>
    <description>This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.</description>
    <arm_group_label>VNS Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 22 to 65 years of age

          2. Have been diagnosed as suffering from sensorineural tinnitus and at least some tonal
             quality of the tinnitus

          3. Unilateral or bilateral tinnitus

          4. Have experienced tinnitus for at least one year and failed at least one  tinnitus
             therapy (such as a counseling or sound therapy procedure.  The diagnosis of tinnitus
             will include an audiological or medical diagnosis in their health records, as well as
             a patient affirmation of tinnitus greater than 12 months

          5. MML &gt;= 7 dB (decibel)

          6. Have tinnitus score of 40 or greater on the Tinnitus Handicap Questionnaire; (THQ)

          7. No tinnitus treatment for at least 4 weeks prior to study entry.

          8. Willing and able to understand and comply with all study-related procedures during
             the course of the study

        Exclusion Criteria:

          1. Acute or intermittent tinnitus

          2. Severe hearing loss in any ear, as defined as more than an 80 dB HL (decibels hearing
             level) at frequencies from 250 Hz. to 8,000 Hz.

          3. Meniere's disease, ear tumors, or evidence of active middle ear disease (such as
             fluid, infection, tumor, mass)

          4. Any other implanted device such as a pacemaker or other neurostimulator; any other
             investigational device or drug

          5. Pregnant or plan on becoming pregnant or breastfeeding during the study period

          6. Currently require, or likely to require, MRI or diathermy during the study duration

          7. History of adverse reactions to anesthetics (e.g., lidocaine) that in the
             Investigator's opinion make surgery too risky

          8. Beck Depression Inventory (BDI) of 30 or greater

          9. Any other form of tinnitus treatments (e.g. Herbal medication, acupuncture or
             chiropractic medicine) are not allowed during the study.

         10. Any drug known to mimic, increase or decrease release or removal of a diffuse
             neuromodulator, such as norepinephrine, dopamine, serotonin, benzodiazepines, and
             acetylcholine is not allowed, as well as any psychoactive medications.

         11. Significant cardiac history

         12. Use of any medication known to cause or increase tinnitus, such as NSAIDS (ibuprofen,
             naproxen, nabumetone, etc.), aspirin and other salicylates, furosemide (Lasix) and
             other &quot;loop&quot; diuretics, &quot;mycin&quot; antibiotics such as vancomycin, quinine and related
             drugs, and chemotherapy agents such as cisplatin.

         13. Involvement in litigation (e.g., worker's compensation claim and/or receiving
             disability benefits related to tinnitus and/or hearing loss).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W Brent Tarver, BSEE</last_name>
    <role>Study Director</role>
    <affiliation>MicroTransponder Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>W Brent Tarver</last_name>
    <email>studies@microtransponder.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>U. Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U. Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tinnitustrial.com</url>
    <description>Link to study website</description>
  </link>
  <reference>
    <citation>Engineer ND, MÃ¸ller AR, Kilgard MP. Directing neural plasticity to understand and treat tinnitus. Hear Res. 2013 Jan;295:58-66. doi: 10.1016/j.heares.2012.10.001. Epub 2012 Oct 23. Review.</citation>
    <PMID>23099209</PMID>
  </reference>
  <reference>
    <citation>Engineer ND, Riley JR, Seale JD, Vrana WA, Shetake JA, Sudanagunta SP, Borland MS, Kilgard MP. Reversing pathological neural activity using targeted plasticity. Nature. 2011 Feb 3;470(7332):101-4. doi: 10.1038/nature09656. Epub 2011 Jan 12.</citation>
    <PMID>21228773</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinnitus</keyword>
  <keyword>Medical Device</keyword>
  <keyword>Randomized</keyword>
  <keyword>Vagus Nerve Stimulation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
